Related Experiment Video
Updated: Jan 12, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.7K
CAD is Associated with Cancer Prognosis and Promotes Enzalutamide Resistance in Prostate Cancer
Bing-Xue Ma1, Yi-You Mao2, Ze-Fan Zhang3,4
1Department of Physical Education, Guangzhou Institute of Physical Education, Guangzhou, 510515, Guangdong, China.
Recent Patents on Anti-Cancer Drug Discovery
|November 2, 2025
Summary
Carbamoyl-phosphate synthetase 2, Aspartate transcarbamoylase, and Dihydroorotase (CAD) is upregulated in most cancers, showing diagnostic and prognostic potential. Targeting CAD inhibits prostate cancer growth and enzalutamide resistance.
Area of Science:
- Oncology
- Molecular Biology
- Bioinformatics
Background:
- Preliminary research explored Carbamoyl-phosphate synthetase 2, Aspartate transcarbamoylase, and Dihydroorotase (CAD)-targeted therapies in limited cancer types.
- A comprehensive understanding of CAD's diagnostic, prognostic, and mechanistic roles across cancers is needed.
Purpose of the Study:
- To conduct a pan-cancer analysis of CAD expression using bioinformatics tools.
- To experimentally validate CAD's role in enzalutamide resistance in prostate cancer.
- To review CAD's molecular classification and drug patents.
Main Methods:
- Pan-cancer bioinformatics analysis of CAD expression.
- Experimental validation of CAD in enzalutamide-resistant prostate cancer cells.
- Review of molecular classification and drug patents using Worldwide Espacenet ®.
Main Results:
- CAD is upregulated in most tumor tissues and its expression correlates with clinical stage, grade, and prognosis.
- CAD expression links to tumor mutation burden, MSI, HRD, and immune cell infiltration, suggesting synergy with immunotherapy.
- CAD knockdown inhibits prostate cancer cell growth and enzalutamide resistance, highlighting its role in angiogenesis and EMT.
Conclusions:
- CAD demonstrates significant diagnostic and prognostic potential in a pan-cancer context.
- CAD plays a crucial role in prostate cancer proliferation and resistance to enzalutamide therapy.
Related Concept Videos
01:21Cancer Survival Analysis
639
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
639
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K